Daniel C. Chan

6.5k total citations
82 papers, 5.3k citations indexed

About

Daniel C. Chan is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniel C. Chan has authored 82 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Molecular Biology, 31 papers in Oncology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel C. Chan's work include Peptidase Inhibition and Analysis (12 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (11 papers) and Lung Cancer Treatments and Mutations (9 papers). Daniel C. Chan is often cited by papers focused on Peptidase Inhibition and Analysis (12 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (11 papers) and Lung Cancer Treatments and Mutations (9 papers). Daniel C. Chan collaborates with scholars based in United States, Japan and China. Daniel C. Chan's co-authors include Paul A. Bunn, Rajesh Agarwal, Rana P. Singh, Chapla Agarwal, Anil K. Tyagi, Barbara A. Helfrich, Dmitri B. Kirpotin, Anna E. Barón, Wilbur A. Franklin and B. Helfrich and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Blood.

In The Last Decade

Daniel C. Chan

81 papers receiving 5.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel C. Chan United States	42	3.0k	1.6k	1.4k	622	602	82	5.3k
Claudio Festuccia Italy	45	2.8k 0.9×	1.6k 1.0×	1.1k 0.8×	1.1k 1.7×	230 0.4×	164	5.3k
Eugenio Erba Italy	39	2.1k 0.7×	1.3k 0.8×	609 0.4×	785 1.3×	364 0.6×	138	4.6k
Christopher L. Morton United States	45	3.2k 1.1×	1.5k 0.9×	915 0.7×	663 1.1×	935 1.6×	128	5.6k
Raymond J. Hohl United States	40	2.3k 0.8×	1.5k 0.9×	624 0.4×	818 1.3×	225 0.4×	138	4.9k
Gÿorgý Kéri Hungary	41	3.5k 1.2×	1.7k 1.0×	482 0.3×	535 0.9×	130 0.2×	162	6.1k
Cristiano Ferlini Italy	41	3.0k 1.0×	1.7k 1.1×	508 0.4×	1.0k 1.6×	279 0.5×	136	5.3k
David G. Menter United States	43	2.1k 0.7×	2.6k 1.6×	984 0.7×	1.4k 2.3×	598 1.0×	136	5.9k
Michael Grusch Austria	41	2.9k 1.0×	1.1k 0.7×	646 0.5×	783 1.3×	236 0.4×	161	4.7k
Khalil Ahmed United States	43	5.1k 1.7×	1.5k 0.9×	333 0.2×	519 0.8×	241 0.4×	240	6.9k
Devarajan Karunagaran India	39	3.4k 1.1×	2.2k 1.3×	453 0.3×	970 1.6×	238 0.4×	99	5.9k

Countries citing papers authored by Daniel C. Chan

Since Specialization

Citations

This map shows the geographic impact of Daniel C. Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel C. Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel C. Chan more than expected).

Fields of papers citing papers by Daniel C. Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel C. Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel C. Chan. The network helps show where Daniel C. Chan may publish in the future.

Co-authorship network of co-authors of Daniel C. Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel C. Chan. A scholar is included among the top collaborators of Daniel C. Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel C. Chan. Daniel C. Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suda, Kenichi, Leslie Rozeboom, Christopher J. Rivard, et al.. (2017). Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer. 109. 1–8. 26 indexed citations

Leonard, Shannon C., Helen Lee, Daniel F. Gaddy, et al.. (2017). Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Anti-Cancer Drugs. 28(10). 1086–1096. 25 indexed citations

Helfrich, Barbara A., Jihye Kim, Dexiang Gao, et al.. (2016). Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Molecular Cancer Therapeutics. 15(10). 2314–2322. 83 indexed citations

Helfrich, Barbara A., Matias Casás‐Selves, Alwin G. Schuller, et al.. (2016). AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition. Clinical Cancer Research. 23(6). 1531–1541. 50 indexed citations

Mateen, Samiha, Komal Raina, Chapla Agarwal, Daniel C. Chan, & Rajesh Agarwal. (2013). Silibinin Synergizes with Histone Deacetylase and DNA Methyltransferase Inhibitors in Upregulating E-cadherin Expression Together with Inhibition of Migration and Invasion of Human Non-small Cell Lung Cancer Cells. Journal of Pharmacology and Experimental Therapeutics. 345(2). 206–214. 63 indexed citations

Casás‐Selves, Matias, Jihye Kim, Zhiyong Zhang, et al.. (2012). Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition. Cancer Research. 72(16). 4154–4164. 109 indexed citations

Moody, Terry W., Marc J. Berna, Samuel A. Mantey, et al.. (2010). Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. European Journal of Pharmacology. 637(1-3). 38–45. 48 indexed citations

Argast, Gretchen, Carrie H. Croy, Kasey L. Couts, et al.. (2009). Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. Oncogene. 28(30). 2697–2709. 43 indexed citations

Gera, Lajos, et al.. (2009). N-(Fluorenyl-9-methoxycarbonyl)amino Acid Amide Derivatives as a New Class of Anti-cancer Agents. Advances in experimental medicine and biology. 611. 465–466. 3 indexed citations

10.

Moody, Terry W., et al.. (2006). Bombesin/Gastrin-Releasing Peptide Receptor Antagonists Increase the Ability of Histone Deacetylase Inhibitors to Reduce Lung Cancer Proliferation. Journal of Molecular Neuroscience. 28(3). 231–238. 21 indexed citations

11.

Stewart, John M., Lajos Gera, Daniel C. Chan, et al.. (2005). Combination cancer chemotherapy with one compound: Pluripotent bradykinin antagonists. Peptides. 26(8). 1288–1291. 32 indexed citations

12.

Kusy, Sophie, Patrick Nasarre, Daniel C. Chan, et al.. (2005). Selective Suppression of In Vivo Tumorigenicity by Semaphorin SEMA3F in Lung Cancer Cells. Neoplasia. 7(5). 457–465. 59 indexed citations

13.

Stewart, John M., et al.. (2004). New Lung Cancer Drugs From Bradykinin Antagonists. CHEST Journal. 125(5). 148S–148S. 10 indexed citations

14.

Sharma, Girish, Anil K. Tyagi, Rana P. Singh, Daniel C. Chan, & Rajesh Agarwal. (2004). Synergistic Anti-Cancer Effects of Grape Seed Extract and Conventional Cytotoxic Agent Doxorubicin Against Human Breast Carcinoma Cells. Breast Cancer Research and Treatment. 85(1). 1–12. 124 indexed citations

15.

Stewart, John M., Daniel C. Chan, Paul A. Bunn, et al.. (2002). Bradykinin antagonists as new drugs for prostate cancer. International Immunopharmacology. 2(13-14). 1781–1786. 20 indexed citations

16.

Stewart, John M., Lajos Gera, Daniel C. Chan, et al.. (2002). Bradykinin-related compounds as new drugs for cancer and inflammation. Canadian Journal of Physiology and Pharmacology. 80(4). 275–280. 41 indexed citations

17.

Bunn, Paul A., B. Helfrich, Wilbur A. Franklin, et al.. (2001). Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.. PubMed. 7(10). 3239–50. 131 indexed citations

18.

Moody, Terry W., et al.. (2001). SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides. 22(1). 109–115. 49 indexed citations

19.

Magriples, Urania, et al.. (1997). Circulating Thrombomodulin Levels and Clinical Correlates in Pregnant Diabetics. American Journal of Perinatology. 14(10). 605–608. 2 indexed citations

20.

Chan, Daniel C., et al.. (1984). The Role of the Central Globular Domain of Histone H5 in Chromatin Structure. Journal of Biomolecular Structure and Dynamics. 2(2). 319–332. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact